Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Amber, Jessup"'
Autor:
Andrew, Mulcahy, Christine, Buttorff, Kenneth, Finegold, Zeid, El-Kilani, Jon F, Oliver, Stephen, Murphy, Amber, Jessup
Publikováno v:
The American journal of managed care. 28(7)
Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain. We projected US biosimilar savings from 2021 to 2025 un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::921c8a0e5476ab4c328a2fbec2c7de6e
https://pubmed.ncbi.nlm.nih.gov/35852882
https://pubmed.ncbi.nlm.nih.gov/35852882
Autor:
Zeid El-Kilani, Jacqueline L. Chen, Ernst R. Berndt, Mark R. Trusheim, Ariel Dora Stern, Amber Jessup, Melissa Ouellet
Publikováno v:
Health Affairs. 40:989-999
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars—foll...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::762d1a5bf84b209edbe679327ee5b57d
https://doi.org/10.1377/hlthaff.2020.02239
https://doi.org/10.1377/hlthaff.2020.02239
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
Autor:
Lubna Merchant, Allison R Kolbe, Jing Xu, Aaron Kearsley, Archita Patel, Amber Jessup, Eva Temkin
Publikováno v:
BioDrugs. 35:363-372
Biosimilars have the potential to increase patient access and significantly reduce healthcare costs in the US. However, uptake in the US has been slower than anticipated, limiting the benefits of biosimilar competition. Understanding the factors that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997321c982cb51fca4c98c3835b21293
https://doi.org/10.1007/s40259-021-00479-6
https://doi.org/10.1007/s40259-021-00479-6
Publikováno v:
JAMA Network Open. 5:e2231609
The US medical device market is the world's largest, but estimates of the cost to bring a medical device to market are not available to help inform policy making and regulatory efforts to enhance device safety and innovation.To estimate the mean expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bce24d4e5051adf6fa9d032b418913c
https://doi.org/10.1001/jamanetworkopen.2022.31609
https://doi.org/10.1001/jamanetworkopen.2022.31609
Autor:
Ariel Dora, Stern, Jacqueline L, Chen, Melissa, Ouellet, Mark R, Trusheim, Zeid, El-Kilani, Amber, Jessup, Ernst R, Berndt
Publikováno v:
Health affairs (Project Hope). 40(6)
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars-follow-on products to biologic drugs-as a vehicle for con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2cdca55c2cb088169d9b8692dee3e7a1
https://pubmed.ncbi.nlm.nih.gov/34097520
https://pubmed.ncbi.nlm.nih.gov/34097520
Publikováno v:
Applied Health Economics and Health Policy. 15:113-118
The development pipeline for antibacterial drugs has not met the demand of hospitals and healthcare providers struggling to cope with increasing problems of antibacterial resistance. Although the challenges associated with antibacterial drug developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b586b9634b28afb36cf6770028d0cb
https://doi.org/10.1007/s40258-016-0279-5
https://doi.org/10.1007/s40258-016-0279-5
Publikováno v:
American Journal of Preventive Medicine. 50:S20-S26
The question of how to evaluate lost consumer surplus in benefit-cost analyses has been contentious. There are clear health benefits of regulations that curb consumption of goods with health risks, such as tobacco products and foods high in fats, cal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be01a3c9abd26a8eea4fc5da73f2b30b
https://doi.org/10.1016/j.amepre.2015.12.002
https://doi.org/10.1016/j.amepre.2015.12.002
Publikováno v:
Clinical Trials. 13:117-126
Background: The increasing cost of clinical research has significant implications for public health, as it affects drug companies’ willingness to undertake clinical trials, which in turn limits patient access to novel treatments. Thus, gaining a be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66fd26e63f3cd7317d66a347e6d403c6
https://doi.org/10.1177/1740774515625964
https://doi.org/10.1177/1740774515625964
Publikováno v:
Journal of Benefit-Cost Analysis. 6:247-280
The analysis of regulations affecting addictive or habitual goods has drawn considerable controversy. Some studies have suggested that such regulations have only small welfare benefits, as consumers value these goods despite health benefits from quit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9efb797bc3ea92c40af975edd8300e7
https://doi.org/10.1017/bca.2015.44
https://doi.org/10.1017/bca.2015.44
Autor:
Amber Jessup, Robert L. Scharff
Publikováno v:
Medical Care. 45:860-868
Background: Cost-effectiveness evaluation for health care programs often involves the use of quality-adjusted life-year (QALY) estimates to measure morbidity losses from health conditions. Current techniques for measuring morbidity losses are often s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4536eeebbb68914989c9f71bce5e4956
https://doi.org/10.1097/mlr.0b013e3180618bac
https://doi.org/10.1097/mlr.0b013e3180618bac